Study of antimycobacterial, cytotoxic, and mutagenic potential of polymeric nanoparticles of copper (II) complex

References

• Alasino, R.V., et al., 2012. Eudragit E100 surface activity and lipid interactions. Colloids surf B biointerfaces, 91, 84–89.
   PubMed Web of Science ®Google Scholar
• Barar, J., 2015. Bioimpacts of nanoparticle size: why it matters? Bioimpacts, 5, 113–115.
   PubMedGoogle Scholar
• Bernstein, L., et al., 1982. An empirical approach to the statistical analysis of mutagenesis data from the Salmonella test. Mutation research., 97 (4), 267–281.
   PubMedGoogle Scholar
• Cetin, M., Atila, A., and Kadioglu, Y., 2010. Formulation and in vitro characterization of Eudragit® L100 and Eudragit® L100-PLGA nanoparticles containing diclofenac sodium. AAPS PharmSciTech, 11, 1250–1256.
   PubMed Web of Science ®Google Scholar
• Cruz, L., et al., 2009. High encapsulation efficiency of sodium alendronate in Eudragit S100/HPMC blend microparticles. Química nova, 32 (5), 1170–1174.
   Web of Science ®Google Scholar
• Dai, J., et al., 2004. PH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. International journal of pharmaceutics., 280 (1–2), 229–240.
   PubMed Web of Science ®Google Scholar
• Darwin, K.H., 2015. Mycobacterium tuberculosis and copper: a newly appreciated defense against an old foe? The journal of biological chemistry, 290, 18962–18966.
   PubMed Web of Science ®Google Scholar
• De Grandis, R.A., et al., 2016. In vitro evaluation of the cyto-genotoxic potential of Ruthenium(II) SCAR complexes: a promising class of antituberculosis agents. Mutation research. Genetic toxicology and environmental mutagenesis, 798–799, 11–18.
   PubMed Web of Science ®Google Scholar
• Diaz, D.A., et al., 2016. Dissolution similarity requirements: how similar or dissimilar are the global regulatory expectations? The AAPS journal, 18, 15–22.
   PubMed Web of Science ®Google Scholar
• Drzewiecka-Antonik, A., et al., 2017. Synthesis, structural studies and biological activity of novel Cu(II) complexes with thiourea derivatives of 4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione. Journal of inorganic biochemistry, 176, 8–16.
   PubMed Web of Science ®Google Scholar
• Firmino, G.S.S., et al., 2016. Synthesis and evaluation of copper(II) complexes with isoniazid-derived hydrazones as anticancer and antitubercular agents. Biometals, 29, 953–963.
   PubMed Web of Science ®Google Scholar
• Fregonezi, N.F., et al., 2020. Cyto-genotoxic evaluation of novel anti-tubercular copper (II) complexes containing isoniazid-based ligands. Regulatory toxicology and pharmacology, 113, 104653
   PubMed Web of Science ®Google Scholar
• Hwang, T.L., et al., 2015. Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles. International journal of nanomedicine, 10, 371–385.
   PubMed Web of Science ®Google Scholar
• Jain, A.K., and Thareja, S., 2019. In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery. Artificial cells, nanomedicine, and biotechnology, 47, 524–539.
   PubMed Web of Science ®Google Scholar
• Kadian, S.S., & Harikumar, S.L., 2009. Eudragit and its pharmaceutical significance. http://www.pharmainfo.net/satishsinghkadian/publications/eudragit-and-its-pharmaceutical-significance
   Google Scholar
• Lee, J.H., and Yeo, Y., 2015. Controlled drug release from pharmaceutical nanocarriers. Chemical engineering science, 125, 75–84.
   PubMed Web of Science ®Google Scholar
• Maron, D.M., and Ames, B.N., 1983. Revised methods for the Salmonella mutagenicity test. Mutation research, 113, 173–215.
   PubMed Web of Science ®Google Scholar
• Mašková, E., et al., 2019. Highly soluble drugs directly granulated by water dispersions of insoluble Eudragit® polymers as a part of hypromellose K100m matrix systems. Biomed research international, 2019, 8043415.
   PubMed Web of Science ®Google Scholar
• Mortelmans, K., and Zeiger, E., 2000. The Ames Salmonella/microsome mutagenicity assay. Mutation research, 455, 29–60.
   PubMed Web of Science ®Google Scholar
• Ngwuluka, N.C., et al., 2016. Eudragit E100 and polysaccharide polymer blends as matrices for modified-release drug delivery I: physicomechanical properties. Tropical journal of pharmaceutical research, 14 (12), 2155–2162.
   Web of Science ®Google Scholar
• Oliveira, B.G., 2015. O estado da arte da ligação de hidrogênio. Quimica nova, 38, 1313–1322. https://doi.org/https://doi.org/10.5935/0100-4042.20150146
   Google Scholar
• Oliveira, J.S., et al., 2006. Slow-onset inhibition of 2-trans-Enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex. Current pharmaceutical design, 12, 2409–2424.
   PubMed Web of Science ®Google Scholar
• Palomino, J.C., et al., 2002. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy., 46, 2720–2722. https://doi.org/https://doi.org/10.1128/AAC.46.8.2720-2722.2002
   PubMed Web of Science ®Google Scholar
• Rabahi, M.F., et al., 2017. Tuberculosis treatment. Jornal brasileiro de pneumologia, 43 (6), 472–486.
   PubMed Web of Science ®Google Scholar
• Rodenak-Kladniew, B., et al., 2017. Design, characterization and in vitro evaluation of linalool-loaded solid lipid nanoparticles as potent tool in cancer therapy. Colloids surf B Biointerfaces, 154, 123–132.
   PubMed Web of Science ®Google Scholar
• Rodrigues, D.F., et al., 2020. Novel Eudragit® -based polymeric nanoparticles for sustained release of simvastatin. Brazilian journal of pharmaceutical sciences, 56, 1–12. https://doi.org/https://doi.org/10.1590/s2175-97902019000418363
   Web of Science ®Google Scholar
• Sato, M.R., et al., 2017. Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis. Drug design, development and therapy, 11, 909–921.
   PubMed Web of Science ®Google Scholar
• Sato, M.R., et al., 2019. Copper(II) complex-loaded castor oil-based nanostructured lipid carriers used against Mycobacterium tuberculosis: development, characterisation, in vitro and in vivo biological assays. Die pharmazie, 74, 715–720. https://doi.org/https://doi.org/10.1691/ph.2019.9110
   PubMed Web of Science ®Google Scholar
• Schaffazick, S.R., et al., 2003. Caracterização e estabilidade físico-química de sistemas poliméricos nanoparticulados para administração de fármacos. Química nova, 26 (5), 726–737.
   Web of Science ®Google Scholar
• Shams, T., et al., 2018. Electrosprayed microparticles for intestinal delivery of prednisolone. Journal of the royal society interface, 15 (145), 20180491.
   PubMed Web of Science ®Google Scholar
• Silva Melo, C., da Silva Cunha Junior, A., and Ligório Fialho, S., 2012. Formas farmacêuticas poliméricas para a administração de peptídeos e proteínas terapêuticos. Journal of basic and applied pharmaceutical sciences revista de ciências farmacêuticas básica e aplicada, 33, 469–477.
   Google Scholar
• Silva, P.B., et al., 2021. Highlights regarding the use of metallic nanoparticles against pathogens considered a priority by the world health organization. Current medicinal chemistry, 28 (10), 1906–1956.
   PubMed Web of Science ®Google Scholar
• Silva, P.B., et al., 2015. A nanostructured lipid system as a strategy to improve the in vitro antibacterial activity of copper(II) complexes. Molecules, 20, 22534–22545.
   PubMed Web of Science ®Google Scholar
• Silva, P.B., et al., 2016. Nanotechnology-based drug delivery systems for treatment of tuberculosis-a review. Journal of biomedical nanotechnology., 12, 241–260.
   PubMed Web of Science ®Google Scholar
• Singh, N., et al., 2017. Chapter 27 – drug delivery: advancements and challenges. Nanostructures for drug delivery, 9780323461436, 865–886. https://doi.org/https://doi.org/10.1016/B978-0-323-46143-6.00027-0
   Google Scholar
• Singh, R., and Lillard, J.W., 2009. Nanoparticle-based targeted drug delivery. Experimental and molecular pathology, 86, 215–223.
   PubMed Web of Science ®Google Scholar
• Toledo, C., et al., 2021. Binary medical nanofluids by combination of polymeric Eudragit nanoparticles for vehiculization of tobramycin and resveratrol: antimicrobial, hemotoxicity and protein corona studies. Journal of pharmaceutical sciences, 110, 1739–1748.
   PubMed Web of Science ®Google Scholar
• Ying, X.Y., et al., 2011. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydrate polymers., 84 (4), 1357–1364.
   Web of Science ®Google Scholar
• Yoshida, T., et al., 2013. pH- and ion-sensitive polymers for drug delivery. Expert opinion on drug delivery, 10, 1497–1513.
   PubMed Web of Science ®Google Scholar
• Zeiger, E., 2019. The test that changed the world: the Ames test and the regulation of chemicals. Mutation research. Genetic toxicology and environmental mutagenesis, 841, 43–48.
   PubMed Web of Science ®Google Scholar